|
Open Access- Title
|
Correlation of Histological type, Grade and Results of IHC and SISH regarding Cerb2-HER2/neu Amplification |
|
|
Author
|
Ioannis Manolis, Georgia Kafiri, Chryssoula Glava, Efthymios Koniaris, Maria Venetikou, Nikolaos Thalassinos, Fragkiski Anthouli-Anagnostopoulou Pathological Anatomy Laboratory, Hippokration General Hospital, Athens, Greece |
|
|
Citation
|
I. Manolis, G. Kafiri, Chr Glava, E, Koniaris, M. Venetikou, N. Thalassinos, F. Anthouli-Anagnostopoulou. Correlation of Histological type, Grade and Results of IHC and SISH regarding Cerb2-HER2/neu Amplification. Review Clin. Pharmacol. Pharmacokinet. 2023, 37, 1, 11-31. DOI: 10.5281/zenodo.10041726 |
|
|
Publication Date
Republication Date
|
02-02-2023
25-10- 2023
|
|
|
Full Text Language
|
English |
|
|
Keywords
|
breast cancer, histological types, special histological types, HER2 amplification, IHC, SISH, Ki-67, estrogen receptors, progesterone receptors
|
|
|
Other Terms
|
Research Article |
|
|
Summary
|
Breast cancer is one of the most common causes of death worldwide. The increasing incidence of breast cancer and its associated mortality highlights the need for new diagnostic procedures and immunohistochemical techniques improving the therapeutic management, especially the targeted treatment. To highlight and assess the expression of oncogene HER2, regarding to the results of Immunohistochemistry (IHC) scoring 2+ and Silver DNA in Situ Hybridization (SISH) technique and identify breast cancer type, special histological types, grade, and the correlation regarding to histological type, grade, and other biomarkers such as estrogen and progesterone receptors, and Ki-67. | |
| References | 1. Jiani Wang & Binghe Xu. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduction and Targeted Therapy. 4:34 (2019).2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71: 209–249 (2021).3. Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control. 22:399–405 (2011). 4. De Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 137:183–192 (2011). 5. Makki J. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol. 8(1):23- 31 (2015). 6. Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer Basic Clin Res. 9 (Suppl. 2):17-34 (2015). 7. Henry NL, Cannon-Albright L. Breast Cancer Histologic Subtypes Show Excess Familial Clustering. Wiley Cancer. 125(18):3131-3138 (2019). 8. Masood S. Breast Cancer Subtypes: Morphologic and Biologic Characterization. Womens Health. 12(1):103-119 (2016). 9. Renan Gomes do Nascimento, Kaléu MorminoOtoni. Histological and molecular classification of breast cancer: what do we know? Mastology. 30: 1-8: e20200024 (2020). 10. West A, Wullkopf L, Christensen A, Leijnse N, Tarp JM, Mathiesen J, et al. Division induced dynamics in non-Invasive and invasive breast cancer. Biophys J. 112:123–125 (2017). 11. Chuba P, Hamre M, Yap J, Severson R, Lucas D, Shamsa F. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 23:5534–5541 (2005). 12. Clauser P, Marino MA, Baltzer PA, Bazzocchi M, Zuiani C. Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ. Exp Rev Anticancer Ther. 16:335–336 (2016). 13. Nakhlis F, Morrow M. Ductal carcinoma in situ. Surg Clin. 83:821–839 (2003). 14. Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. Breast Cancer. 20:1–6 (2017). 15. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 6:149–152 (2004). 16. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. J Clin Oncol. 34:1134–1150 (2016). 17. Andrew McGuire, James A. L. Brown, Carmel Malone, Ray McLaughlin, and Michael J. Kerin. Effects of Age on the Detection and Management of Breast Cancer. Cancers (Basel). 7(2): 908–929 (2015).18. Stevanovic A, Lee P, Wilcken N. Metastatic breast cancer. Aust Fam Phys. 35:309–311 (2006). 19. Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Arch. 465(1):1-14 (2014). 20. Mateo A, Pezzi T, Sundermeyer M, Kelley C, Klimberg V, Pezzi C. Chemotherapy significantly improves survival for patients with T1c-T2 N0M0 medullary Breast cancer. Ann Surg Oncol. 24 (4):1050–1056 (2017). 21. Anuradha D, Lakshmi A. Mucinous carcinoma of breast with neuroendocrine differentiation: a rare case report with review of literature. Int JRes Med Sci. 2:1751–1754 (2017). 22. Priya V, Prasaad P. Tubulo-lobular carcinoma: a rare mixed invasive carcinoma of breast. Int J Res Med Sci. 5:2818–2820 (2017). 23. Joglekar-Javadekar M, Van Laere S, Bourne M, Moalwi M, FinettiP, Vermeulen PB, et al. Characterization and targeting of platelet-derived growth factor receptor alpha (PDGFRA) in inflammatory breast cancer (IBC). Neoplasia. 19: 564–573 (2017). 24. Errichetti E, Avellini C, Pegolo E, De Francesco V. Dermoscopy as a supportive instrument in the early recognition of erosive adenomatosis of the nipple and mammary Paget’s disease. Ann Dermatol. 29:365–367 (2017). 25. Strode M, Khoury T, Mangieri C, Takabe K. Update on the diagnosis and management of malignant phyllodes tumors of the breast. J Breast. 33:91–96 (2017). 26. Sera T, Kashiwagi S, Takashima T, Asano Y, Goto W, Iimori N, et al. Multiple metastatic malignant phyllodes tumor of the breast with tonsillar metastasis: a case report. BMC Res Notes. 10 :55 (2017). 27. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281 (2008). 28. Panjwani P, Epari S, Karpate A, ShirsatH, Rajsekharan P, Basak R, et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral center in India. Indian J Med Res; 132:287-294 (2010). 29. Ji Y, Sheng L, Du X, Qiu G, Chen B, Wang X. Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer. J Thorac Dis 6:896-904 (2014). 30. Jang JS, Jang EJ, Park J. HER2 expression in breast cancer: Comparisons of fluorescence in situ hybridization and silver in situ hybridization, and immunohistochemical staining using monoclonal antibody and polyclonal antibody. Basic Appl Pathol 3: 115–120 (2010). 31. Powell RD, Pettay JD, Powell WC, Roche PC, Grogan TM, Hainfeld JF, et al. Metallographic in situ hybridization. Hum Pathol 38:1145-1149 (2007). 32. IBM SPSS Statistics 28. Brief guide, U.S., 2020. 33. Anna M. Badowska-Kozakiewicz, Anna Liszcz, Maria Sobol, and Janusz Patera. Retrospective evaluation of histopathological examinations in invasive ductal breast cancer of no special type: an analysis of 691 patients. Arch Med Sci. 13(6): 1408–1415 (2017). 34. SoominAhn, Ji Won Woo, Kyoungyul Lee, and So Yeon Park.HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 54(1): 34–44 (2020).35. Sergiusz Łukasiewicz, Marcin Czecze lewski, Alicja Forma, Jacek Baj, Robert Sitarz, and Andrzej Stanisławek. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers (Basel). 13(17): 4287 (2021).36. Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC. Hormones, Receptors, and Growth in Hyperplastic Enlarged Lobular Units: Early Potential Precursors of Breast Cancer. Breast Cancer Res BCR 8: R6 (2006). 37. Huh SJ, Oh H, Peterson MA, Almendro V, Hu R, Bowden M, et al. The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women. Cancer Res 76:1926–1934 (2016). 38. Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, et al. Ki-67 Expression and Docetaxel Efficacy in Patients with Estrogen Receptor-Positive Breast Cancer. J Clin Oncol 27:2809–2815 (2009). 39. Oh H, Eliassen AH, Wang M, Smith-Warner SA, Beck AH, Schnitt SJ, et al. Expression of Estrogen Receptor, Progesterone Receptor, and Ki-67 in Normal Breast Tissue in Relation to Subsequent Risk of Breast Cancer. NPJ Breast Cancer. 2:16032 (2016). 40. Thu an Dang Cong, Tung Nguyen Thanh, Quynh Anh Nguyen Phan, Ai Phuong Hoang Thi, Bao Song Nguyen Tran, and Quoc Huy Nguyen Vu. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam. Asian Pac J Cancer Prev. 21(4): 1135–1142 (2020). 41. Isabel Pinhel, Margaret Hills, Suzanne Drury, Janine Salter, Georges Sumo, Roger A’Hern, et al, the NCRI Adjuvant Breast Cancer Trial Management Group. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res. 14(2): R46 (2012). |
|
|
Relative Papers
|